Table 2.

Potential Differences in Immunogenicity Among Vaccines for Shared Serotypes in Key Phase 3 Randomized Controlled Clinical Trials

				Shared Serotypes Failing Noninferiority Criteria With Higher-Valency PCV
Author	PCVs	Vaccination Schedule, mo	Timing of Assessment	Response Ratea	IgG GMC Ratiob
Vesikari (2009) [21]	PCV7	2, 3, 4	1 mo after primary series	6B, 23Fc,d	NR
	PCV10	+12–18
Kieninger (2010) [22]	PCV7	2, 3, 4	1 mo after primary series	6B	None
	PCV13	+11–12
Yeh (2010) [23]	PCV7	2, 4, 6	1 mo after primary series	6B, 9V	None
	PCV13	+12–15
Temple (2019) [1]	PCV10	2, 4	1 mo after primary series	Noned	NR
	PCV13	+9.5
Lupinacci (2023) [24]	PCV13	2, 4, 6	1 mo after primary series	Noned	6Ad
	V114	+12–15
Benfield (2023) [25]	PCV13	3, 5	1 mo after toddler dose	Noned	Noned
	V114	+12
Martinon-Torres (2023) [26]	PCV13	2, 4	1 mo after toddler dose	Noned	Noned
	V114	+11–15
Watson (2023) [27]	PCV13	2, 4, 6	1 mo after primary series	1, 3, 4, 9V, 23Fd,e	None
	PCV20	+12–15	1 mo after toddler dose	NRd	Noned

Abbreviations: GMC, geometric mean concentration; IgG, immunoglobulin G; NR, not reported; PCV; pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; V114, 15-valent pneumococcal conjugate vaccine.

^aIgG response threshold is 0.35 μg/mL unless otherwise stated.

^bNoninferiority criteria differed across studies.

^cIgG response threshold is 0.20 μg/mL for noninferiority; serotypes listed did not meet noninferiority criteria.

^dPrimary or coprimary immunogenicity endpoint.

^eDifferent thresholds used for serotypes 5, 6B, and 19A.